comparemela.com

Latest Breaking News On - மார்பிக் சிகிச்சை - Page 1 : comparemela.com

Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor ...

Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Canada
Tom-donovan
Johnp-jones
Peter-linde
Chris-erdman
Adrians-ray
Exchange-commission
International-dial
Colitis-organisation
Securities-exchange
Morphic-integrin-technology-mint-platform
Virtual-congress

(MORF) - Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study

(MORF) - Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Colitis-organization
Virtual-congress
Morphic-therapeutic
European-crohn
பெருங்குடல்-அழற்சி-ஆர்கநைஸேஶந்
மெய்நிகர்-காங்கிரஸ்
மார்பிக்-சிகிச்சை
ஐரோப்பிய-குரோன்

Schrodinger Inc (SDGR) Q1 2021 Earnings Call Transcript

Operator Thank you for standing by. Welcome to Schrodinger s conference call to review the company s first quarter financial results. My name is Kevin, and I ll be your operator for today s call. [Operator Instructions] Now, I would like to introduce your host for today s conference call, Jaren Madden, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead. Jaren Madden Senior Vice President, Investor Relations and Corporate Communications Thank you, and hello, everyone. Welcome to today s call during which we will provide an update on the company and review our financial results for the first quarter of 2021. Earlier this morning, we issued a press release summarizing our financial results and progress across the company, which is available on our website at www.schrodinger.com. Here with me on our call today are Ramy Farid, President and Chief Executive Officer; Karen Akinsanya, Executive Vice President, Chief Biomedical Scientist and Hea

United-states
America
American
Joel-lebowitz
Karen-akinsanya
Michael-ryskin
Jaren-madden
Michael-yee-jefferies
Ramy-farid
Michael-yee
Schrodinger-inc
American-society-of-hematology

Morphic Therapeutic Announces Appointment of Susannah Gray

Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term April 28, 2021 16:01 ET | Source: Morphic Therapeutic Morphic Therapeutic Waltham, Massachusetts, UNITED STATES WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its Board of Directors. Ms. Gray is an accomplished leader in healthcare finance and serves as a director on the boards of multiple healthcare companies. Ms. Gray was most recently the executive vice president of finance and strategy at Royalty Pharma.

Susannah-gray
Susang-komen
Vikas-goyal
Praveen-tipirneni
Chris-erdman
Gustav-christensen
Tom-donovan
Otello-stampacchia
Exchange-commission
Merrill-lynch
Columbia-university-business-school
Maravai-lifesciences

Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors

Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Susannah-gray
Susang-komen
Vikas-goyal
Praveen-tipirneni
Gustav-christensen
Contactsmorphic-therapeuticchris
Otello-stampacchia
Contacttom-donovan
Exchange-commission
Merrill-lynch
Columbia-university-business-school
Maravai-lifesciences
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.